Danaher (NYSE: DHR ) should see good growth moving forward. Its Biotech segment is seeing good momentum, driven by double-digit growth in consumables. Equipment orders are also starting to bounce back, and I expect equipment revenues to return to growth, further We focus on GARP (Growth at reasonable Price) opportunities in industrial, consumer, and technology sectors. We are among the top 50 financial experts (Out of ~39,000 tracked) as measured by Tipranks based on the consistency of our stock recommendat ...